Papcup has introduced a non-invasive, at-home device designed to screen for cancer-causing HPV strains using regular menstrual blood. This device, developed with support from the Venture Builder Incubator (VBI) at the University of Edinburgh, aims to provide an alternative to traditional smear tests, which many women find uncomfortable and inconvenient. The device offers a highly accurate, non-invasive method for testing, allowing women…
Digital health company Sidekick Health has announced its acquisition of PINK!, a digital therapeutics company specializing in cancer support and women’s health. This strategic move is set to enhance Sidekick Health’s portfolio and strengthen its position in the DTx market. PINK! Coach, a prescription digital therapeutic (PDT) for breast cancer within Germany’s regulated nationwide DiGA (Digitale Gesundheitsanwendungen) formulary, will now be part…
Digital therapeutics company Mika Health has announced a new collaboration with AstraZeneca and Daiichi Sankyo. The initiative, named “UNITE,” aims to enhance the treatment experience for women undergoing breast cancer therapy in Switzerland through the use of Mika Health’s AI-enabled mobile platform. The UNITE initiative was unveiled at the HLTH Europe conference and signifies a significant step towards integrating digital solutions in…
You’ve found some of our exclusive Inner Circle Content. This article is only available for our Inner Circle Members. To read on: Sign in to your Inner Circle account to access this content. If you aren’t a member yet and would like to find out more about our Inner Circle program or sign up, click here.
GC Aesthetics, a company specializing in the design, manufacture, and distribution of breast implants and medical devices, has launched a new product aimed at improving breast reconstruction for women. The FixNip Nipple and Areola Reconstruction Implant (NRI) addresses a significant clinical need by providing a long-term aesthetic solution. FixNip NRI features a biocompatible smooth silicone structure with a floral-shaped nitinol frame. This…
Lunit, a provider of AI-powered cancer diagnostics and therapeutics, has acquired Volpara Health Technologies, a global leader in breast cancer screening software. Last year when the acquisition was first announced Lunit shared plans to acquire all Volpara shares at AUD 1.15 per share, amounting to a deal worth approximately AUD 292 million (USD 193 million). The acquisition merges Volpara’s advanced breast health…
In a significant advancement for women’s health, both BD (Becton, Dickinson and Company) and Roche have announced FDA approvals for their respective self-collection solutions for human papillomavirus (HPV) testing, aiming to improve access and participation in cervical cancer screening. BD’s FDA approval allows women to self-collect vaginal specimens for HPV testing when traditional cervical specimens are not obtainable. This self-collection can be…
Amplexd Therapeutics has secured $2 million in funding from an Asia-based family office specializing in life sciences. This investment supports the finalization of product development and the initiation of Phase 1/2 clinical trials for non-invasive treatments targeting Cervical Intraepithelial Neoplasia (CIN). “The funding marks a major milestone in our R&D efforts for our two therapies after extremely promising preclinical studies were completed.…
